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Schizophrenia shows a genetic correlation with both anxiety disorder and neuroti-
cism, a trait strongly associated with anxiety. However, genetic correlations do not
discern causality from genetic confounding. We therefore aimed to investigate
whether anxiety-related phenotypes lie on the causal pathway to schizophrenia using
Mendelian randomization (MR). Four MR methods, each with different assumptions
regarding instrument validity, were used to investigate casual associations of anxiety
and neuroticism related phenotypes on schizophrenia, and vice versa: inverse vari-
ance weighted (IVW), weighted median, weighted mode, and, when appropriate, MR
Egger regression. MR provided evidence of a causal effect of neuroticism on schizo-
phrenia (IVW odds ratio [OR]: 1.33, 95% confidence interval [CI]: 1.12–1.59), but
only weak evidence of a causal effect of anxiety on schizophrenia (IVW OR: 1.10,
95% CI: 1.01–1.19). There was also evidence of a causal association from schizophre-
nia liability to anxiety disorder (IVW OR: 1.28, 95% CI: 1.18–1.39) and worry (IVW
beta: 0.05, 95% CI: 0.03–0.07), but effect estimates from schizophrenia to neuroti-
cism were inconsistent in the main analysis. The evidence of neuroticism increasing
schizophrenia risk provided by our results supports future efforts to evaluate
neuroticism- or anxiety-based therapies to prevent onset of psychotic disorders.
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1 | BACKGROUND
Schizophrenia is a heritable psychotic disorder characterized by posi-
tive (e.g., hallucinations and delusions) and negative (e.g., apathy and
flattened affect) symptoms. It is associated with significant health,
social and financial burden (Chong et al., 2016). Anxiety symptoms are
prevalent among people with schizophrenia (Temmingh &
Stein, 2015) with meta-analyses demonstrating that anxiety symp-
toms reach the threshold of disorder in an estimated 38% of patients
(Achim et al., 2011). Anxiety disorders are also present in people with
first episode psychosis (Michail & Birchwood, 2014) and those at high
risk for psychosis (Fusar-Poli, Nelson, Valmaggia, Yung, &
McGuire, 2014; Gajwani, Patterson, & Birchwood, 2013) and have
been shown to precede psychosis onset (Welham, Isohanni, Jones, &
McGrath, 2009), suggesting they do not occur only as a consequence
of psychotic disorder onset or treatment.
Neuroticism is a personality trait that describes a dispositional
tendency to become aroused quickly when stimulated and to be slow
in inhibiting emotions. Individuals scoring highly on neuroticism expe-
rience negative emotional states, such as worry and guilt, particularlyHannah J. Jones and David Martin should be considered joint first author.
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in response to threat or frustration (Ormel, Bastiaansen, et al., 2013).
Neuroticism is strongly associated with common mental disorders
such as anxiety and depression (Kotov, Gamez, Schmidt, &
Watson, 2010; Lahey, 2009) and longitudinal studies have shown it to
be associated with an increased risk of subsequent psychotic symp-
toms (Goodwin, Fergusson, & Horwood, 2003; Krabbendam
et al., 2002) and schizophrenia (Lönnqvist et al., 2009; Van Os &
Jones, 2001).
Schizophrenia shows moderate genetic correlation with anxiety
disorder (Otowa et al., 2016; Purves et al., 2019), neuroticism, and the
genetically distinguishable “worry” subtype of neuroticism (Nagel, Jan-
sen, et al., 2018). Genetic risk for schizophrenia has also been shown
to be associated with a higher risk of anxiety disorders in adolescence
and adulthood (Jones et al., 2016; Richards et al., 2019), while genetic
risk for neuroticism is associated with negative symptoms in adoles-
cence (Jones et al., 2018).
It has been suggested that anxiety might be on the causal path-
way to schizophrenia (Hall, 2017), although it is also possible that anx-
iety arises secondary to the expression of schizophrenia genetic
liability (e.g., through poor social cognition skills, such as deficits in
emotion processing [Germine et al., 2016]), or that the association
between anxiety and schizophrenia is due to confounding, including
genetic confounding. For example, a genetic variant influencing anxi-
ety may be in linkage disequilibrium (LD) (i.e., non-randomly corre-
lated) with a genetic variant influencing schizophrenia, or a genetic
variant may independently influence both anxiety and schizophrenia
(termed horizontal pleiotropy).
If strong evidence is found that anxiety has a causal effect on the
development of schizophrenia, then this would highlight the need for
a more proactive approach to treating anxiety, both to prevent onset
of psychosis in those at higher-risk, and to prevent relapse in those
with schizophrenia. However, as it is difficult to tease out causal
effects from reverse causation or confounding using traditional epide-
miological approaches, more robust methods are needed. Mendelian
randomization (MR) uses genetic variants as instrumental variables to
investigate causal relationships between modifiable risk factors and
health outcomes (Davey Smith & Ebrahim, 2003; Lawlor, Harbord,
Sterne, Timpson, & Davey Smith, 2008). The core assumptions of MR
are i) the genetic instrumental variables must be associated with the
risk factor of interest, ii) they share no common cause with the out-
come (i.e., are independent of confounders), and iii) they only affect
the outcome through the risk factor (the exclusion restriction assump-
tion). If these assumptions are met, this approach can overcome issues
of reverse causation and unmeasured confounding. Two-sample MR
is an extension of MR that allows the instrument-exposure and
instrument-outcome associations to be measured in two independent
samples (Pierce & Burgess, 2013). An advantage of a two-sample
approach is that it can be implemented using summary data from large
scale genome-wide association studies (GWASs) (Burgess, But-
terworth, & Thompson, 2013), providing an opportunity to substan-
tially increase statistical power. We therefore aimed to examine
whether anxiety or neuroticism have a causal effect on schizophrenia
using a two-sample MR study design.
2 | METHODS
2.1 | Genetic instrument data sources
2.1.1 | Anxiety
Genetic instruments for anxiety were taken from the 2019 lifetime anxi-
ety disorder GWAS by Purves et al. (2019) who reported 5 independent
loci that were genome-wide significantly (p value ≤5 × 10−8) associated
with lifetime anxiety disorder within UK Biobank (Western European
ancestry; 25,453 cases, 58,113 controls; single nucleotide polymorphism
[SNP]-based heritability on observed scale = 0.12). Lifetime anxiety disor-
der was defined by a self-reported lifetime professional diagnosis of one
of the five core anxiety disorders (generalized anxiety disorder, social
phobia, panic disorder, agoraphobia or specific phobia) or meeting criteria
for a likely lifetime diagnosis of DSM-IV generalized anxiety disorder
based on anxiety questions from the Composite International Diagnostic
Interview Short-form questionnaire (Purves et al., 2019). Following a
meta-analysis of the UK Biobank GWAS and GWASs from two addi-
tional studies (all European ancestry; total sample of 31,977 cases,
82,114 controls), the study reported 2 genome-wide significant SNPs. As
one of the genome-wide significant SNPs (chromosome 5: rs7723509)
had palindromic alleles with intermediate allele frequencies, this SNP
was not taken forward in the analysis. The remaining genome-wide sig-
nificant SNP (chromosome 9: rs10959577) was used within a single
SNP, two-sample MR analysis (see below). Full GWAS summary statistics
were obtained from the corresponding authors of the GWAS manuscript
(Purves et al., 2019).
2.1.2 | Neuroticism
Genetic instruments for neuroticism were taken from a recent GWAS
by Luciano et al. (2018) who reported 116 independent (R2 < .1 within
a 500 kb window) SNPs that were genome-wide significantly associ-
ated with a total neuroticism score based on the 12-item Eysenck Per-
sonality Questionnaire Revised Short Form (EPQ-R-S) within UK
Biobank (white British ancestry; n = 329,821 participants; SNP-based
heritability = 0.11). Full GWAS summary statistics are available from:
http://www.ccace.ed.ac.uk/node/335.
2.1.3 | Depressed affect and worry
Genetic instruments for 2 sub-clusters of neuroticism (depressed
affect and worry) (Nagel, Watanabe, Stringer, Posthuma, & van der
Sluis, 2018) were taken from Nagel, Jansen, et al. (2018) who per-
formed a GWAS in UK Biobank using 4 EPQ-R-S items relating to a
depressed affect sub-cluster (European ancestry; n = 357,957 partici-
pants; SNP-based heritability = 0.09) and 4 EPQ-R-S items relating to
a worry sub-cluster (European ancestry; n = 348,219 participants;
SNP-based heritability = 0.09). Following functional mapping of
genome-wide significance SNPs, the study reported 75 independent
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(R2 < .1) lead SNPs for depressed affect and 73 independent (R2 < .1)
lead SNPs for worry. Full GWAS summary statistics are available from:
https://ctg.cncr.nl/software/summary_statistics.
2.1.4 | Schizophrenia
Genetic instruments for schizophrenia were taken from the 2014 Psy-
chiatric Genomics Consortium GWAS which reported 128 indepen-
dent (R2 < .1 within a 500 kb window) SNPs that were genome-wide
significantly associated with schizophrenia case/control status after a
meta-analysis of 49 case/control GWASs (European ancestry; 33,640
cases, 43,456 controls; SNP-based heritability on observed
scale = 0.45) (Schizophrenia Working Group of the Psychiatric Geno-
mics Consortium, 2014). Full GWAS summary statistics are available
from: https://www.med.unc.edu/pgc/results-and-downloads/.
2.2 | Bidirectional, two-sample MR
To investigate the direction of causality between schizophrenia and the
anxiety-related phenotypes, a bidirectional two-sample MR approach
was used where the anxiety-related phenotypes were treated as the
exposures in one set of analyses and schizophrenia was treated as the
exposure in another set of analyses. GWAS summary statistics relating
to genome-wide significant SNPs associated with anxiety disorder, neu-
roticism (as well as depressed affect and worry sub-clusters) and schizo-
phrenia were used as exposure instruments.
SNPs were included in the analysis if they had a minor allele fre-
quency (MAF) ≥ 0.05. SNP alleles, phenotype association effect sizes,
standard errors and p values for each exposure genetic instrument were
extracted from the corresponding exposure GWASs. To ensure that the
SNPs were independent, SNPs were pruned for LD using the - -r2 com-
mand in PLINK (v1.9) (Chang et al., 2015; Purcell et al., 2007) with
1000genomes (phase 1 version 3) as a reference panel. SNPs were
deemed as being in LD if they were correlated at R2 > .01 within a
10,000 kb window. The SNP with the largest GWAS standard error from
each correlated SNP pair was excluded from the analyses.
Following LD pruning, exposure SNP information (mainly SNP-
phenotype effect sizes, standard errors and p values, effect and alternative
alleles and effect allele frequency) was harmonized with the corresponding
SNP information, if available, from the outcome GWAS summary statistics
using the 2sampleMR MR-Base R package (Hemani et al., 2018). During
harmonization, SNPs were excluded based on allele differences, strand dif-
ferences and if palindromic SNPs had a MAF > 0.42. See Table S1 for the
number of SNPs retained for each analysis.
All MR analyses were carried out using the 2sampleMR MR-Base
R package. For the single SNP analysis, a ratio estimate was calculated
by dividing the SNP-schizophrenia effect estimate by the SNP-anxiety
effect estimate with standard errors derived using the first term from
a delta method expansion for the ratio estimate (Thomas, Lawlor, &
Thompson, 2007). For multi-SNP analyses, four regression-based
methods were used to pool and assess causal estimates between
anxiety disorder, neuroticism phenotypes and schizophrenia. These
included inverse variance weighted (IVW), weighted median, weighted
mode, and MR Egger regression methods. Briefly, the IVW method is
equivalent to a weighted linear regression of SNP-outcome associa-
tions on SNP-exposure associations with the assumption that all SNPs
are valid instruments, that is, there is no directional pleiotropy
(Burgess et al., 2013; Lawlor et al., 2008). Because of this assumption,
the intercept of the IVW regression is constrained to zero (i.e., if there
is no effect of the SNP on the exposure, there will be no effect of the
SNP on the outcome). The weighted median method estimates the
causal effect from the median of the weighted empirical density func-
tion of SNP-outcome/SNP-exposure ratio estimates (Bowden, Davey
Smith, Haycock, & Burgess, 2016). This method thus allows up to 50%
of the information in the analysis to come from invalid SNPs. The
weighted mode method estimates the causal effect from the mode of
the weighted empirical density function of SNP-outcome/SNP-
exposure ratio estimates and assumes that the weights associated
with valid instruments are the largest among all subsets of instru-
ments (the ZEro Modal Pleiotropy Assumption) (Hartwig, Davey
Smith, & Bowden, 2017). The MR Egger regression method is an
expansion of the IVW method which does not assume that all instru-
ments are valid and thus does not constrain the regression intercept
to zero (Bowden, Davey Smith, & Burgess, 2015). The method there-
fore provides a causal estimate that takes pleiotropic effects into
account with the intercept giving an estimate of the average pleiotro-
pic effect (i.e., effect of the SNP on the outcome when there is no
effect of the SNP on the exposure). The MR Egger method gives a
valid causal estimate if the SNP-exposure associations are not corre-
lated to the direct effects of the genetic variants on the outcome
(i.e., pleiotropic effects). This is termed the Instrument Strength Inde-
pendent of Direct Effect (InSIDE) assumption (Bowden et al., 2015).
2.3 | Assessing instrument strength and
heterogeneity
Weak instrument bias within the IVW analyses was quantified using the
mean F statistic (F) (Bowden, Del Greco, et al., 2016) with F >10 indi-
cating that the IVW analysis does not suffer substantially from weak
instrument bias. The degree of violation of the IVW and MR-Egger
assumption that the SNP-exposure association is measured without
error (the “NO Measurement Error” [NOME] assumption) was
assessed using F minus 1 divided by F ((F−1)/F) (IVW) and I2GX statis-
tic (MR Egger) (Bowden, Del Greco, et al., 2016). These statistics
range from 0 to 1, with values close to 1 indicating minimal attenua-
tion in the effect estimate due to violation of the NOME assumption
(Bowden et al., 2017; Bowden, Del Greco, et al., 2016). In situations
where I2GX was relatively large (here we have defined this as >70%),
simulation extrapolation (SIMEX) was also used as a method of bias
adjustment for the MR Egger estimate in the presence of violation of
the NOME assumption.
Presence of heterogeneity between individual SNP-outcome on
SNP-exposure effect estimates was assessed using Cochran's (IVW)
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and Rücker's (MR Egger) Q tests (Bowden et al., 2017; Del Greco,
Minelli, Sheehan, & Thompson, 2015).
2.4 | Exclusion of instruments in linkage
disequilibrium between exposure and outcome
As a sensitivity analysis to minimize potential violation of the second
(instruments are independent of confounders) and third (instruments
only affect the outcome through the exposure) core MR assumptions,
two-sample MR analyses were repeated after excluding pairs of SNPs
that were in LD between each exposure/outcome instrument set.
Although these shared loci (that are strongly associated with both the
exposures and outcomes in our analyses) may reflect truly causal loci,
they may also index risk for something (such as a behavior) that increases
risk of both anxiety and schizophrenia, or they might reflect horizontal
pleiotropy (influencing the two phenotypes through independent path-
ways) or confounding by LD (associated with phenotypes through LD) (-
Figure S1). These violations would in turn bias the bidirectional analyses.
LD between SNP instruments for anxiety/neuroticism pheno-
types and schizophrenia was assessed using the methods described
previously. Any SNP pair that was correlated at R2 > .01 within a
10,000 kb window between the anxiety/neuroticism phenotype
instruments and schizophrenia instruments were excluded from the
sensitivity analysis (Tables S2–S5).
3 | RESULTS
3.1 | Instrument strength and heterogeneity
All F statistics were >10 indicating that weak instrument bias was not
affecting the IVW analyses (Table S6). With regards to violation of the
NOME assumption, ((F −1)/F ) and I2GX statistics indicated that mea-
surement error in the SNP-exposure associations was not
substantially attenuating the neuroticism to schizophrenia effect esti-
mate ((F −1)/F = 0.97, I2GX = 0.72). However, all other I2GX statistics
were low (I2GX range = 0.00–0.19) indicating that MR Egger effect
estimates were potentially affected by violation of the NOME
assumption (Table S6). We therefore have only presented the MR
Egger estimates when investigating neuroticism as an exposure but
present results of all other MR methods that are more robust to viola-
tions of NOME for other exposures.
There was strong evidence of heterogeneity in causal effect sizes
across all analyses with the exception of the analysis investigating anxi-
ety disorder as the exposure and schizophrenia as the outcome
(Cochran's Q = 2.74; p value = .60; Table S6). Sensitivity plots depicting
individual SNP effect estimates, “leave one out” analyses and instrument
precision for each of the analyses are presented in Figures S6–S14.
3.2 | Anxiety as exposure
Table 1 and Figure S2a display the MR results of the association between
genetically increased odds of having an anxiety disorder and schizophrenia.
Across all MR approaches, estimated effect sizes were in the direction of a
causal association between anxiety disorder and schizophrenia; however,
the confidence intervals (CIs) often included protective effects (single SNP
method odds ratio [OR]: 1.19, 95% CI: 0.93–1.52; IVW OR: 1.10, 95% CI:
1.01–1.19; weighted median OR: 1.05, 95% CI: 0.94, 1.16; weighted mode
OR: 1.04, 95% CI: 0.90–1.21). Results were similar in the sensitivity ana-
lyses omitting instruments that were highly correlated between anxiety
disorder and schizophrenia (i.e., potential shared loci between the expo-
sure and the outcome) (Table 1 and Figure S2b).
3.3 | Neuroticism phenotypes as exposures
When investigating the association between genetically elevated
levels of neuroticism and schizophrenia, all MR approaches showed
TABLE 1 Odds ratios of
schizophrenia per increased odds of
anxiety disorder as estimated by multiple
Mendelian randomization methods
Exposure Outcome MR method No. SNPs OR (95% CI) p
Following harmonization with outcome data
Anxiety Schizophrenia Ratio estimate 1 1.19 (0.93, 1.52) .164
IVW 5 1.10 (1.01, 1.19) .028
Weighted median 1.05 (0.94, 1.16) .372
Weighted mode 1.04 (0.90, 1.21) .624
Following harmonization with outcome data and removal of shared locia
Anxiety Schizophrenia IVW 4 1.11 (1.01, 1.21) .027
Weighted median 1.09 (0.98, 1.21) .129
Weighted mode 1.05 (0.89, 1.23) .610
Note: MR Egger analyses were not performed due to large violation of the NOME assumption.
Abbreviations: 95% CI, 95% confidence interval; IVW, inverse variance weighted; MR, Mendelian ran-
domization; No. SNPs, number of single nucleotide polymorphism used in the analysis as instruments;
OR, odds ratio.
aShared loci were defined as correlated anxiety and schizophrenia instruments (R2 > .01 within a
10,000 kb window).
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evidence that neuroticism increased the odds of schizophrenia (IVW
OR: 1.33, 95% CI: 1.12–1.59; weighted median OR: 1.34, 95% CI:
1.16, 1.55; weighted mode OR: 1.43, 95% CI: 1.06–1.93; MR Egger
OR: 2.06, 95% CI: 0.37, 11.53) (Table 2 and Figure S3a). The MR
Egger regression intercept provided little evidence of directional hori-
zontal pleiotropy (MR Egger intercept OR: 0.99, 95% CI: 0.93, 1.05).
Estimates using MR Egger with SIMEX were consistent with MR
Egger results without adjusting for bias induced by violation of the
NOME assumption, though 95% CIs were wider (MR Egger OR: 5.32,
95% CI: 0.30, 93.59; MR Egger intercept OR: 0.95, 95% CI:
0.86, 1.05).
Sensitivity plots evaluating individual SNP effect estimates and
leave-one-out analyses showed that no individual SNPs were driving
the associations, and symmetry within the funnel plot evaluating
instrument precision indicated little evidence of directional pleiotropy
(Figure S7).
Similar results were observed when investigating the effects of
genetically elevated levels of the neuroticism sub-clusters, depressed
affect and worry, although evidence from the weighted mode analysis
was weaker (Table 2, Figure S3b,c).
Results were similar to the primary analyses in the sensitivity ana-
lyses omitting instruments that were highly correlated between the
neuroticism phenotypes and schizophrenia (Table 2, Figure S3d–f),
however, the evidence of a causal effect of depressed affect and
worry on schizophrenia substantially weakened.
3.4 | Schizophrenia as exposure
Tables 3 and 4 and Figures S4 and S5 display the MR results of the
association between genetically increased odds of having schizophre-
nia and anxiety and neuroticism phenotypes. There was evidence,
with consistent effect sizes across MR methods, of a causal associa-
tion between schizophrenia liability and anxiety disorder (IVW OR:
1.28, 95% CI: 1.18–1.39; weighted median OR: 1.21, 95% CI: 1.10,
1.34), although evidence was weaker when using the weighted mode
method (OR: 1.18, 95% CI: 0.94–1.49). Results were similar in sensi-
tivity analyses omitting instruments that were highly correlated
between anxiety disorder and schizophrenia (Table 3, Figure S4b). No
individual SNPs were driving this association and symmetry within the
funnel plot indicated little evidence of directional pleiotropy
(Figure S10).
The strongest evidence of a causal association from schizophrenia
liability to neuroticism was observed when using the IVW MR method
(beta: 0.05, 95% CI: 0.01–0.09); however, there was little evidence
observed when using the other MR methods with inconsistencies
between direction of effect (Table 4, Figure S5a).
Similar to the association between schizophrenia and anxiety dis-
order, there was however, more consistent evidence of an effect of
genetic liability for schizophrenia on levels of worry with strong evi-
dence presented from the IVW and weighted median analyses (IVW
beta: 0.05, 95% CI: 0.03–0.07; weighted median beta: 0.04, 95% CI:
0.02–0.05; weighted mode beta: 0.04, 95% CI: 0.00–0.07) (Table 4,
Figure S5c), but not on depressed affect (Table 4, Figure S5a,b). No
individual SNPs were driving this association, however there was
some asymmetry within the funnel plot indicating evidence of direc-
tional pleiotropy (Figure S14).
In sensitivity analyses omitting loci correlated between neuroti-
cism and schizophrenia phenotypes, results were similar to primary
analyses with no strong evidence of effect of higher genetic liability
to schizophrenia leading to changes in levels of neuroticism or
depressed affect, though the directions of the effect estimates were
now consistent, but strong evidence that genetic liability to schizo-
phrenia is associated to higher levels of worry (Table 4, Figure S5d–f).
4 | DISCUSSION
The results of this two-sample MR study provide evidence of an asso-
ciation between schizophrenia and anxiety phenotypes as well as an
association between neuroticism and schizophrenia.
Although anxiety has long been reported as a common feature of
the schizophrenia prodrome (Docherty, Van Kammen, Siris, &
Marder, 1978; Fusar-Poli et al., 2014; Tien & Eaton, 1992; Turnbull &
Bebbington, 2001), using genetic instruments to proxy anxiety disor-
der, we found only weak evidence that increased odds of having anxi-
ety increases risk of schizophrenia. The majority of the MR
approaches we used however, indicated that a higher neuroticism
score increases odds of schizophrenia. This result is in agreement with
longitudinal studies that report an association between higher levels
of neuroticism and increased risk of development of psychotic symp-
toms (Goodwin et al., 2003; Krabbendam et al., 2002) and schizophre-
nia (Lönnqvist et al., 2009; Van Os & Jones, 2001), as well as a
previous MR of neuroticism and schizophrenia that used a generalized
summary-data-based MR [GSMR] approach (Nagel, Jansen,
et al., 2018). In contrast to the other methods, the MR Egger approach
showed little evidence of association between neuroticism and
schizophrenia. However, the power to detect causal effects using MR
Egger, as well as the SIMEX bias adjustment method, is very sensitive
to the amount of violation in the NOME assumption which is poten-
tially still too large in the current study (Bowden, Del Greco,
et al., 2016).
The conceptual understanding of the relationship between neu-
roticism and anxiety symptoms or disorder is not well understood.
Theoretical models positing either that neuroticism is a separate con-
struct that acts as a risk factor for anxiety disorders, or that neuroti-
cism and anxiety symptoms/disorder lie on different parts of a
spectrum or continuum are both partly supported by empirical evi-
dence (Ormel, Jeronimus, et al., 2013). The difficulty in teasing apart
neuroticism from anxiety is further complicated by the substantial
overlap in questions used to measure these phenotypes, and the
strong association between neuroticism and anxiety disorder in cross-
sectional studies (Cohen's d >1.9 for most anxiety disorders) (Kotov
et al., 2010). The findings from our neuroticism MR may therefore be
consistent with anxiety having a causal effect on schizophrenia, par-
ticularly in light of the fact that the neuroticism instruments were
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taken from a substantially larger GWAS than the anxiety disorder one.
Future investigations utilizing joint analysis approaches, such as geno-
mic structural equation modeling (Grotzinger et al., 2019) and multi-
trait-based conditional and joint analysis (Zhu et al., 2018), may be
fruitful in shedding light on the shared and specific genetic architec-
ture of these phenotypes once anxiety GWAS sample sizes increase.
We also found evidence that increased genetic liability to schizo-
phrenia leads to higher levels of anxiety and the neuroticism sub-
cluster relating to worry, a core feature of anxiety. Similar findings
have been reported in our studies using polygenic scores for
schizophrenia where genetic liability for the disorder is modeled using
scores based on many risk-increasing SNPs, each with small effect.
These previous studies showed that, within the general population, a
higher genetic liability to schizophrenia is associated with anxiety dis-
order and with a latent construct of anxiety in adolescence (Jones
et al., 2016; Jones et al., 2018), and with anxiety disorders, most
strongly with GAD and panic disorder, in adulthood (Richards
et al., 2019).
Together, these results imply that while neuroticism may confer a
casual effect on risk of developing schizophrenia, higher neuroticism
TABLE 2 Odds ratios of schizophrenia per unit increase in neuroticism phenotype score as estimated by multiple Mendelian randomization
methods
Exposure Outcome MR method No. SNPs OR (95% CI) p
Following harmonization with outcome data
Neuroticism Schizophrenia IVW 71 1.33 (1.12, 1.59) .001
Weighted median 1.34 (1.16, 1.55) 6.17e−05
Weighted mode 1.43 (1.06, 1.93) .023
MR Egger slope 2.06 (0.37, 11.53) .416
MR Egger intercept 0.99 (0.99, 1.05) .623
Depressed affect sub-cluster IVW 54 1.54 (0.96, 2.46) .073
Weighted median 1.62 (1.11, 2.36) .012
Weighted mode 2.03 (0.90, 4.57) .094
MR Egger slopea — —
MR Egger intercepta — —
Worry sub-cluster IVW 57 2.54 (1.60, 4.03) 7.11e−05
Weighted median 1.57 (1.11, 2.23) .011
Weighted mode 1.26 (0.65, 2.44) .494
MR Egger slopea — —
MR Egger intercepta — —
Following harmonization with outcome data and removal of shared locib
Neuroticism Schizophrenia IVW 50 1.30 (1.08, 1.56) .006
Weighted median 1.36 (1.14, 1.63) .001
Weighted mode 1.52 (1.09, 2.13) .016
MR Egger slope 0.93 (0.17, 4.94) .929
MR Egger intercept 1.01 (0.95, 1.07) .694
Depressed affect sub-cluster IVW 34 1.12 (0.65, 1.94) .680
Weighted median 1.52 (0.96, 2.40) .076
Weighted mode 2.11 (0.97, 4.60) .070
MR Egger slopea — —
MR Egger intercepta — —
Worry sub-cluster IVW 36 1.22 (0.78, 1.91) .392
Weighted median 1.22 (0.82, 1.83) .332
Weighted mode 1.13 (0.51, 2.54) .766
MR Egger slopea — —
MR Egger intercepta — —
Abbreviations: 95% CI, 95% confidence interval; IVW, inverse variance weighted; MR, Mendelian randomization; No. SNPs, number of single nucleotide
polymorphism used in the analysis as instruments; OR, odds ratio.
aMR Egger analyses not performed due to large violation of the NOME assumption.
bShared loci were defined as correlated neuroticism phenotype and schizophrenia instruments (R2 > .01 within a 10,000 kb window).
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scores and anxiety are also more likely to occur as a manifestation of
schizophrenia liability, or secondary to the disorder. For example, it is
difficult to envisage anyone hearing abusive voices or believing that
others are trying to harm them without having some symptoms of
anxiety in relation to these experiences.
There is some evidence that psychological treatments developed
to address neuroticism have efficacy in treating anxiety disorders
(Barlow et al., 2017). There is likely to be a large overlap in the
cognitive-behavioral models underlying the treatment of neuroticism
with those for specific anxiety disorders and targeting anxiety
TABLE 3 Odds ratios of anxiety
disorder per increase in odds ratios of
schizophrenia as estimated by multiple
Mendelian randomization methods
Exposure Outcome MR method No. SNPs OR (95% CI)a p
Following harmonization with outcome data
Schizophrenia Anxiety IVW 84 1.28 (1.18, 1.39) 6.15e−09
Weighted median 1.21 (1.10, 1.34) 1.48e−04
Weighted mode 1.18 (0.94, 1.49) .156
Following harmonization with outcome data and removal of shared locia
Schizophrenia Anxiety IVW 83 1.27 (1.17, 1.38) 1.23e−08
Weighted median 1.21 (1.10, 1.34) 1.39e−04
Weighted mode 1.19 (0.94, 1.50) .147
Note: MR Egger analyses were not performed due to large violation of the NOME assumption.
Abbreviations: 95% CI, 95% confidence interval; IVW, inverse variance weighted; MR, Mendelian ran-
domization; No. SNPs, number of single nucleotide polymorphism used in the analysis as instruments;
OR, odds ratio.
aShared loci were defined as correlated anxiety and schizophrenia instruments (R2 > .01 within a
10,000 kb window).
TABLE 4 Change in neuroticism phenotype score per increase in odds ratios of schizophrenia as estimated by multiple Mendelian
randomization methods
Exposure Outcome MR method No. SNPs Beta (95% CI) p
Following harmonization with outcome data
Schizophrenia Neuroticism IVW 82 0.05 (0.01, 0.09) .009
Weighted median 0.01 (−0.02, 0.04) .414
Weighted mode −0.02 (−0.10, 0.06) .679
Depressed affect sub-cluster IVW 82 0.01 (0.00, 0.03) .077
Weighted median −0.01 (−0.02, 0.01) .472
Weighted mode −0.02 (−0.06, 0.03) .457
Worry sub-cluster IVW 82 0.05 (0.03, 0.07) 3.14e−08
Weighted median 0.04 (0.02, 0.05) 6.66e−07
Weighted mode 0.04 (−0.0004, 0.07) .056
Following harmonization with outcome data and removal of shared locia
Schizophrenia Neuroticism IVW 58 0.04 (0.003, 0.08) .034
Weighted median 0.05 (0.01, 0.09) .007
Weighted mode 0.10 (−0.02, 0.21) .109
Depressed affect sub-cluster IVW 61 0.01 (−0.01, 0.02) .299
Weighted median 0.01 (−0.01, 0.03) .184
Weighted mode 0.05 (−0.003, 0.11) .069
Worry sub-cluster IVW 65 0.04 (0.02, 0.06) 4.91e−06
Weighted median 0.04 (0.02, 0.05) 1.93e−06
Weighted mode 0.04 (−0.001, 0.07) .063
Note: MR Egger analyses were not performed due to large violation of the NOME assumption.
Abbreviations: 95% CI, 95% confidence interval; IVW, inverse variance weighted; MR, Mendelian randomization; No. SNPs, number of single nucleotide
polymorphism used in the analysis as instruments; OR, odds ratio.
aShared loci were defined as correlated neuroticism phenotype and schizophrenia instruments (R2 > .01 within a 10,000 kb window).
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symptoms also falls within the remit of cognitive-behavioral therapy
for psychosis (Morrison, 2017). Therapies targeting neuroticism more
explicitly have not yet been evaluated in prevention of psychosis, but
based on our findings, might hold some promise.
High levels of anxiety in people with schizophrenia are associated
with greater hallucinations, withdrawal, depression, hopelessness, and
poorer function (Lysaker & Salyers, 2007). Therefore, while the likely
benefit of targeting the treatment of neuroticism or anxiety to pre-
vent transition to psychosis in people at clinical high-risk is unclear,
psychological (Wykes, Steel, Everitt, & Tarrier, 2008) and pharmaco-
logical (Temmingh & Stein, 2015) therapies for anxiety may be useful
not only in alleviating anxiety symptoms but also potentially in
improving prognosis (Braga, Petrides, & Figueira, 2004) and quality of
life (Braga, Mendlowicz, Marrocos, & Figueira, 2005) in people with a
psychotic disorder.
Although we have used a causal inference design to assess the
relationships between anxiety, neuroticism and schizophrenia, there
are a number of limitations with our study. The first assumption of
MR is that the genetic instrument must be strongly associated with
the exposure (Lawlor et al., 2008). We attempted to satisfy this
assumption by using genetic variants associated with our phenotypes
at genome-wide significance. However, the instruments explain very
little of the variance of these, typically polygenic, phenotypes. For
example, genome-wide significant SNPs explain 3% of variance in
schizophrenia case–control status as compared to 15% explained by
SNPs meeting p < .05 (Schizophrenia Working Group of the Psychiat-
ric Genomics Consortium, 2014). The variance explained by genome-
wide significant SNPs was unfortunately not reported by the anxiety
and neuroticism GWASs, however, SNPs meeting p < .05 explained
only 0.4% of variance in anxiety disorder case–control status
(Purves et al., 2019) and 3% of variance in the neuroticism score
(Luciano et al., 2018). This means that the analyses, especially from
anxiety to schizophrenia, may be subject to weak instrument bias
which biases estimated effects toward the null (Pierce &
Burgess, 2013), although our F statistics for all instruments suggest
that our IVW results were not substantially affected by weak instru-
ment bias. Nevertheless, it would be important to repeat these ana-
lyses using instruments detected in larger, and therefore better
powered, GWASs once data from such studies become available.
We also observed substantial heterogeneity between causal
effect estimates within the majority of analyses. Heterogeneity in
effect estimates may be due to violation of the modeling assumptions
of two-sample MR (e.g., that the exposure and outcome samples are
homogenous) or due to presence of horizontal pleiotropy. Although
the low I2GX prevented us from formally testing for pleiotropic effects
across the majority of analyses, we attempted to minimize pleiotropic
effects and confounding by using sensitivity analyses omitting shared
loci between exposure and outcome. It is possible that these shared
loci represent genetic liability to general psychopathology, commonly
termed the p factor (Caspi et al., 2014), which may confound the true
causal associations between schizophrenia and anxiety. However, if
this were the case, we would expect removal of shared loci to weaken
results in all analyses, which was not observed. Nevertheless, this
approach did not improve our heterogeneity statistics and may have
been limited by the use of the 1,000 genomes project phase 1 as an
LD reference panel as opposed to a larger, more up to date panel such
as that developed by the Haplotype Reference Consortium (McCarthy
et al., 2016). We also tried to minimize heterogeneity between our
samples by using SNP-effect estimates from samples with European
ancestry. Despite this, other selection biases (e.g., using case–control
samples vs. general population samples) may have reduced the level
of homogeneity between our exposure and outcome samples.
Together, the low levels of variance explained by the instruments
and presence of effect heterogeneity makes it difficult to be confident
in interpreting the observed bidirectional relationship between these
complex traits, where the underlying biological mechanisms that the
instruments are proxying are poorly understood. Methods aimed at
identifying and utilizing homogenous sub-groups of instruments to
proxy distinct causal mechanisms, as they develop (Burgess, Foley,
Allara, Staley, & Howson, 2020), will therefore be very useful in the
future when investigating these multifactorial phenotypes.
Finally, it is apparent that the conceptual difference between neu-
roticism and anxiety is not clear with competing models presented
throughout the literature (Ormel, Jeronimus, et al., 2013), while it is
also unclear the extent to which measures used in GWASs of these
phenotypes reflect separate or overlapping constructs. Therefore, as
larger samples of more specific or more accurately measured pheno-
types become available for GWASs, these should make it easier to
tease out causal mechanisms that could be effectively targeted for
interventions.
In conclusion, while there is evidence that schizophrenia liability
increases anxiety, some evidence of neuroticism increasing schizo-
phrenia risk supports further efforts to evaluate neuroticism- or
anxiety-based therapies to prevent onset of psychotic disorders. As
MR effect estimates represent lifetime risk, and should not be inter-
preted literally as the expected outcome of a clinical intervention,
future efforts should focus on triangulation of results from two-
sample MR with other study designs to improve our knowledge of
causal pathways in psychosis etiology (Lawlor, Tilling, & Davey
Smith, 2016).
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